

10/075,909 EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3725	((514/256) or (514/227.8) or (514/235.8) or (514/252.14)).CCLS.	US-PGPUB; USPAT	OR	OFF	2004/12/08 15:57
L2	3760	((544/60) or (544/122) or (544/295) or (544/315) or (544/330)).CCLS.	US-PGPUB; USPAT	OR	OFF	2004/12/08 15:58
L3	6434	L1 or L2	US-PGPUB; USPAT	OR	OFF	2004/12/08 15:58
L4	533	L3 and (dicarboxylic or dicarboxylate or dicarboxyl)	US-PGPUB; USPAT	OR	OFF	2004/12/08 16:01
L5	247	L3 and (benzylamide or benzodioxol or benzooxadiazol or benzothiadiazol)	US-PGPUB; USPAT	OR	OFF	2004/12/08 16:02
L6	33	L5 and (dicarboxylic or dicarboxylate)	US-PGPUB; USPAT	OR	OFF	2004/12/08 16:02

10/075,909

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 6 SEP 27 STANDARDS will no longer be available on STN
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN
NEWS 8 OCT 28 KOREAPAT now available on STN
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current
search transcripts to be affected by CERAB, COMPUAB, ELCOM,
and SOLIDSTATE reloads
NEWS 10 NOV 30 PHAR reloaded with additional data
NEWS 11 DEC 01 LISA now available on STN

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:36:41 ON 08 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:36:48 ON 08 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

10/075,909

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2004 HIGHEST RN 794053-19-3
DICTIONARY FILE UPDATES: 7 DEC 2004 HIGHEST RN 794053-19-3


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\STNEXP4\QUERIES\10075909.str



chain nodes :

7 8 9 10 11 12 13 15

ring nodes :

1 2 3 4 5 6 14 16 17 18 19 20 21 22 23 24 25 26

chain bonds :

2-9 6-7 7-8 7-12 8-13 9-10 9-11 10-15 13-14 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-17 14-21 16-22 16-26 17-18 18-19 19-20 20-21
22-23 23-24 24-25 25-26

exact/norm bonds :

7-8 7-12 8-13 9-10 9-11 10-15

exact bonds :

2-9 6-7 13-14 15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-17 14-21 16-22 16-26 17-18 18-19 19-20 20-21
22-23 23-24 24-25 25-26

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

10/075,909



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 16:37:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 56 TO ITERATE

100.0% PROCESSED 56 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 16:37:18 ON 08 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2004 VOL 141 ISS 24

FILE LAST UPDATED: 7 Dec 2004 (20041207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 1 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637659 CAPLUS

10/075,909

DOCUMENT NUMBER: 137:185500
TITLE: Preparation and formulation of pyrimidine-4,6-dicarboxamides as MMP-13 inhibitors
INVENTOR(S): Barvian, Nicole Chantel; Patt, William Chester
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064571	A1	20020822	WO 2002-IB190	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2433772	AA	20020822	CA 2002-2433772	20020118
EP 1368323	A1	20031210	EP 2002-740096	20020118
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002007209	A	20040127	BR 2002-7209	20020118
JP 2004518723	T2	20040624	JP 2002-564504	20020118
US 2002151555	A1	20021017	US 2002-75909	20020213
PRIORITY APPLN. INFO.:			US 2001-268779P	P 20010214
			WO 2002-IB190	W 20020118

OTHER SOURCE(S): MARPAT 137:185500


AB Z[C(:X)R]₂ [each R independently = OR₄ or NR₄R₅; R₄, R₅ = H, alkyl, (hetero)aryl, etc.; NR₄R₅ = heterocyclyl; X = O or S; Z = 2-(un)substituted pyrimidine-4,6-diyl] were prepared as MMP-13 inhibitors (no data). Thus, pyrimidine-4,6-dicarboxylic acid was amidated by PhCH₂NH₂ to give pyrimidine-4,6-dicarboxylic acid bis(benzylamide).

IT 448949-32-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of pyrimidine-4,6-dicarboxamides as MMP-13 inhibitors)

RN 448949-32-4 CAPLUS

CN 4,6-Pyrimidinedicarboxylic acid, bis(1,3-benzodioxol-5-ylmethyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

10/075,909

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 6 SEP 27 STANDARDS will no longer be available on STN
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN
NEWS 8 OCT 28 KOREAPAT now available on STN
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current
search transcripts to be affected by CERAB, COMPUAB, ELCOM,
and SOLIDSTATE reloads
NEWS 10 NOV 30 PHAR reloaded with additional data
NEWS 11 DEC 01 LISA now available on STN

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:23:57 ON 08 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:24:06 ON 08 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

10/075,909

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2004 HIGHEST RN 794053-19-3
DICTIONARY FILE UPDATES: 7 DEC 2004 HIGHEST RN 794053-19-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> s "pyrimidin-4,6-dicarboxylic" or "pyrimidin-4,6-carboxamide"
      541097 "PYRIMIDIN"
      272860 "4,6"
      279436 "DICARBOXYLIC"
          0 "PYRIMIDIN-4,6-DICARBOXYLIC"
            ("PYRIMIDIN" (W) "4,6" (W) "DICARBOXYLIC")
      541097 "PYRIMIDIN"
      272860 "4,6"
      791200 "CARBOXAMIDE"
          0 "PYRIMIDIN-4,6-CARBOXAMIDE"
            ("PYRIMIDIN" (W) "4,6" (W) "CARBOXAMIDE")
L1      0 "PYRIMIDIN-4,6-DICARBOXYLIC" OR "PYRIMIDIN-4,6-CARBOXAMIDE"

=> s pyrimidin? and (dicarboxylic or dicarboxamide)
      917943 PYRIMIDIN?
      279436 DICARBOXYLIC
      36549 DICARBOXAMIDE
L2      4786 PYRIMIDIN? AND (DICARBOXYLIC OR DICARBOXAMIDE)

=> s l2 and (benzylamide or benzothiadiazol or benzodioxol or benzooxadiazol)
      464 BENZYLAMIDE
      3384 BENZOTHIADIAZOL
      109748 BENZODIOXOL
          1 BENZOOXADIAZOL
L3      53 L2 AND (BENZYLAMIDE OR BENZOTHIADIAZOL OR BENZODIOXOL OR BENZOOX
          ADIAZOL)
```

```
=> file caplus
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                59.27      59.48
```

FILE 'CAPLUS' ENTERED AT 16:26:35 ON 08 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

10/075,909

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2004 VOL 141 ISS 24
FILE LAST UPDATED: 7 Dec 2004 (20041207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 10 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:412923 CAPLUS

DOCUMENT NUMBER: 140:423689

TITLE: Preparation of novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases

INVENTOR(S): Klingler, Otmar; Kirsch, Reinhard; Habermann, Joerg; Weithmann, Klaus-Ulrich; Engel, Christian; Pirard, Bernard

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041788	A1	20040521	WO 2003-EP11515	20031018
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10251019	A1	20040519	DE 2002-10251019	20021102
DE 10254092	A1	20040603	DE 2002-10254092	20021120
PRIORITY APPLN. INFO.:			DE 2002-10251019	A 20021102
			DE 2002-10254092	A 20021120

OTHER SOURCE(S): MARPAT 140:423689

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrimidine-4,6-dicarboxamides I [R1 = H, C1-6-alkyl; R2 = (un)substituted C1-6-alkyl; R3, R4, R5, R6, R7 = H, halogen, (un)substituted C1-6-alkyl; C1-6-haloalkyl, O-(C1-6-alkyl), S-(C1-6-alkyl); R4R5, R5R6 (together to with the carbons to which they are attached) = 5- or 6-membered carbocyclic, aromatic, heterocyclic or heteroaryl ring (hetero compound containing one or more O, S or N)] are suitable for the selective inhibition of

10/075,909

collagenase (MMP 13). Pyrimidine-4,6-dicarboxamides I can be prepared from pyrimidine-4,6-dicarboxylic acid derivs. II (Y = halogen, OH, C1-6-alkoxy; or anhydride) via reaction with R1R2NH or benzylamine III to give the monoamides IV or V, which in turn undergo reaction with benzylamine III or R1R2NH, resp. Thus, VI was prepared from di-Me pyrimidine-4,6-dicarboxylate via partial amidation with 3-MeOC6H4CH2NH2 in THF, saponification with LiOH in THF, amidation with 4-(NH2CH2)C6H4CO2Me·HCl in DMF containing TOTU and NEt3, saponification with LiOH in THF and amidation with Et2NH in DMF containing TOTU and NEt3. The pyrimidine-4,6-dicarboxamides can thus be used for the treatment of degenerative joint diseases. The bioactivity of VI was determined [IC50 = 4 nM vs. MMP 13].


IT 691002-05-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases)

RN 691002-05-8 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:467290 CAPLUS

DOCUMENT NUMBER: 139:53028

TITLE: Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)

INVENTOR(S): Habermann, Joerg; Weithmann, Klaus-Ulrich; Kogler, Herbert; Kirsch, Reinhard; Wehner, Volkmar

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10160357	A1	20030618	DE 2001-10160357	20011208
WO 2003049738	A1	20030619	WO 2002-EP13240	20021125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1455790	A1	20040915	EP 2002-792799	20021125

10/075,909

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 2003229103 A1 20031211 US 2002-65994 20021209
PRIORITY APPLN. INFO.: DE 2001-10160357 A 20011208
US 2002-358887P P 20020222
WO 2002-EP13240 W 20021125

OTHER SOURCE(S): MARPAT 139:53028
GI



late

AB Title compds. [I; A = CH, N; R1-R3 = H, halo, (halogenated) alkyl, alkoxy, OH, CO2R4, cyano, NR5R6, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkylcarbonyl, etc.; or R1R2, R2R3 = 5-6 membered (aromatic) (saturated) (hetero)cyclyl], were prepd for the treatment of degenerative joint diseases. Thus, 4,6-pyrimidinedicarboxylic acid in SOCl2 was stirred for 2 h at 85° followed by addition of CH2Cl2 at room temperature and Et3N at 0°. The reaction mixture was further stirred with 3-chloro-4-fluorobenzylamine for 15 min to give 40% N,N-bis(3-chloro-4-fluorobenzyl)pyrimidine-4,6-dicarboxamide. The latter inhibited collagenase 3 (MMP 13) with IC50 = 23 nM.


IT 448949-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridine- and pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13))

RN 448949-34-6 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)- (9CI)
(CA INDEX NAME)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:322783 CAPLUS

DOCUMENT NUMBER: 139:323478

TITLE: Reactions of Hydrazonoyl Halides 351: Synthesis of
Some New 1,2,4-Triazolino[4,3-a]pyrimidines,
2,3-Dihydro-1,3,4-thiadiazoles and
2,3-Dihydro-1,3,4-selenadiazoles

AUTHOR(S): Rateb, Nora M.; Abdel-Riheem, Nadia A.; Al-Atoom, Ali
A.; Abdelhamid, Abdou O.

CORPORATE SOURCE: Cairo University, Giza, Egypt
SOURCE: Phosphorus, Sulfur and Silicon and the Related
Elements (2003), 178(5), 1101-1114
CODEN: PSSLEC; ISSN: 1042-6507

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

10/075,909

OTHER SOURCE(S): CASREACT 139:323478


AB Hydrazonoyl halides have been caused to react with each of Et 4-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)-6-methyl-2-methylthio-3,4-dihydropyrimidin-5-carboxylate, potassium thiocyanate (or thiourea), potassium selenocyanate, and alkyl carbodithioate in the presence of triethylamine to give 4,3-dihydro-1,2,4-triazolino[4,3-a]pyrimidine, 1,3,4-thiadiazoline, 1,2,4-selenadiazoline, and unsym. azine derivs. in good yields. Structures of the new compds. were elucidated on the basis of elemental analyses, spectral data, and alternative methods of synthesis whenever possible.

IT 615268-51-4P 615268-52-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of triazolinopyrimidines, dihydrothiadiazoles and dihydroselenadiazoles via reaction of hydrazonoyl halides and corresponding pyrimidine carboxylate, selenocyanate, and alkyl carbodithioate)


RN 615268-51-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyrimidine-3,6-dicarboxylic acid,
5-(1,3-benzodioxol-5-yl)-1,5-dihydro-7-methyl-1-phenyl-, 6-ethyl 3-methyl ester (9CI) (CA INDEX NAME)



RN 615268-52-5 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyrimidine-3,6-dicarboxylic acid,
5-(1,3-benzodioxol-5-yl)-1,5-dihydro-7-methyl-1-phenyl-, diethyl ester
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637659 CAPLUS

DOCUMENT NUMBER: 137:185500

TITLE: Preparation and formulation of pyrimidine-4,6-dicarboxamides as MMP-13 inhibitors

INVENTOR(S): Barvian, Nicole Chantel; Patt, William Chester

10/075,909

PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064571	A1	20020822	WO 2002-IB190	20020118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2433772	AA	20020822	CA 2002-2433772	20020118
EP 1368323	A1	20031210	EP 2002-740096	20020118
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002007209	A	20040127	BR 2002-7209	20020118
JP 2004518723	T2	20040624	JP 2002-564504	20020118
US 2002151555	A1	20021017	US 2002-75909	20020213
PRIORITY APPLN. INFO.:			US 2001-268779P	P 20010214
			WO 2002-IB190	W 20020118

OTHER SOURCE(S): MARPAT 137:185500

AB Z[C(:X)R]₂ [each R independently = OR₄ or NR₄R₅; R₄, R₅ = H, alkyl, (hetero)aryl, etc.; NR₄R₅ = heterocyclyl; X = O or S; Z = 2-(un)substituted pyrimidine-4,6-diyl] were prepared as MMP-13 inhibitors (no data). Thus, pyrimidine-4,6-dicarboxylic acid was amidated by PhCH₂NH₂ to give pyrimidine-4,6-dicarboxylic acid bis(benzylamide).


IT 448949-19-7P 448949-26-6P 448949-28-8P
448949-30-2P 448949-31-3P 448949-32-4P
448949-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of pyrimidine-4,6-dicarboxamides as MMP-13 inhibitors)

RN 448949-19-7 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 448949-26-6 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-(2,1,3-benzothiadiazol-5-ylmethyl)- (9CI) (CA INDEX NAME)


*pregnant
Verm*

10/075,909




RN 448949-28-8 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-(1,3-benzodioxol-5-ylmethyl)-N'-(2,1,3-benzoxadiazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 448949-30-2 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-N'-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 448949-31-3 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 448949-32-4 CAPLUS


CN 4,6-Pyrimidinedicarboxylic acid, bis(1,3-benzodioxol-5-ylmethyl) ester (9CI) (CA INDEX NAME)



RN 448949-34-6 CAPLUS

CN 4,6-Pyrimidinedicarboxamide, N,N'-bis(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

10/075,909



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:610405 CAPLUS

DOCUMENT NUMBER: 137:169534

TITLE: Preparation of imidazolyl pyrimidinamines as NOS inhibitors

INVENTOR(S): Arnaiz, Damian O.; Baldwin, John J.; Davey, David D.; Devlin, James J.; Dolle, Roland Ellwood, III; Erickson, Shawn David; McMillan, Kirk; Morrissey, Michael M.; Ohlmeyer, Michael H. J.; Pan, Gonghua; Paradkar, Vidyadhar Madhav; Parkinson, John; Phillips, Gary B.; Ye, Bin; Zhao, Zuchun

PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA; Pharmacopeia, Inc.
SOURCE: U.S., 132 pp., Cont.-in-part of U.S. Ser. No. 25,124, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432947	B1	20020813	US 1999-383813	19990826
CN 1100777	B	20030205	CN 1998-804281	19980219
CA 2376355	AA	20010301	CA 2000-2376355	20000824
WO 2001014371	A1	20010301	WO 2000-US23173	20000824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000014144	A	20020521	BR 2000-14144	20000824
EP 1206467	A1	20020522	EP 2000-959333	20000824
EP 1206467	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
SI 20818	C	20020831	SI 2000-20040	20000824
EE 200200091	A	20030415	EE 2002-91	20000824
NZ 517411	A	20030926	NZ 2000-517411	20000824
AT 256681	E	20040115	AT 2000-959333	20000824
AU 769405	B2	20040129	AU 2000-70671	20000824
ES 2213599	T3	20040901	ES 2000-959333	20000824
ZA 2002001485	A	20030521	ZA 2002-1485	20020221
NO 2002000925	A	20020416	NO 2002-925	20020226
BG 106440	A	20021129	BG 2002-106440	20020226
LT 4982	B	20030127	LT 2002-28	20020315
US 2002165203	A1	20021107	US 2002-121886	20020412
US 2002183323	A1	20021205	US 2002-121659	20020412
US 2003004137	A1	20030102	US 2002-121379	20020412

10/075,909

US 6747031	B2	20040608		
US 2003027794	A1	20030206	US 2002-121758	20020412
US 2003060452	A1	20030327	US 2002-121212	20020412
US 2003069210	A1	20030410	US 2002-122072	20020412
US 2003073669	A1	20030417	US 2002-121682	20020412
US 2003078265	A1	20030424	US 2002-121808	20020412
US 6670473	B2	20031230		
US 2003083332	A1	20030501	US 2002-122047	20020412
US 2003092678	A1	20030515	US 2002-122006	20020412
PRIORITY APPLN. INFO.:			US 1997-808975	B2 19970219
			US 1998-25124	B2 19980217
			WO 1998-US3176	A 19980219
			US 1999-383813	A 19990826
			WO 2000-US23173	W 20000824

OTHER SOURCE(S): MARPAT 137:169534
GI



AB The title compds. [I; U = N, CR5 (R5 = H, halo, alkyl, optionally substituted aralkyl or aryl, etc.); V = NR4, S, O, CHR4 (R4 = H, alkyl, aryl, aralkyl, cycloalkyl); W = N, CH; X, Y, Z = N, CR19 (R19 = H, alkyl, cyclopropyl, halo, haloalkyl); A = R1, OR1, CONR1R2, PO(NR1R2)2, NR1COR2, etc. (R1, R2 = H, optionally substituted alkyl or cycloalkyl, etc. or NR1R2 = N-heterocyclyl); B = CR17(CHR15)mQR3 (m = 1-4, R3 = H, alkyl, cycloalkyl, optionally substituted aryl, etc.; R15, R17 = H, alkyl; Q = CO, O, C:NR1, etc.); C = (CHR12)q(CHR13)r (q, r = 0-1; R12, R13 = H, alkyl); or B = C = null; R14, R20 = H, alkyl; n = 1-3], useful as inhibitors of nitric oxide synthase, were prepared. Thus, N-[(1,3-benzodioxol-5-yl)methyl]-1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetamide was prepared by reaction of 1-(3-aminophenyl)imidazole, Et 7-chloro-3-oxoheptanoate, and piperonylamine. All exemplified compds. I showed iNOS inhibitory activity at concns. less than 25 μM .

IT 212639-01-5P 212639-02-6P 212639-04-8P
212639-06-0P 212639-15-1P 212639-33-3P
212639-35-5P 212639-49-1P 212645-12-0P
212646-48-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl pyrimidinamines as NOS inhibitors)

RN 212639-01-5 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-(1-methylethyl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)

10/075,909




RN 212639-02-6 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)




RN 212639-04-8 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)



RN 212639-06-0 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)



RN 212639-15-1 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-N1-cyclohexyl-4-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/075,909




RN 212639-33-3 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 212639-35-5 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 212639-49-1 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/075,909




RN 212645-12-0 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)



RN 212646-48-5 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS

10/075,909

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:560064 CAPLUS

DOCUMENT NUMBER: 135:137519

TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α 1c antagonists

INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corp., USA

SOURCE: U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 340,611, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6268369	B1	20010731	US 1997-836628	19970516
WO 9614846	A1	19960523	WO 1995-US15025	19951116
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6248747	B1	20010619	US 1999-291553	19990414
US 6727257	B1	20040427	US 2000-730458	20001205
PRIORITY APPLN. INFO.:			US 1994-340611	B2 19941116
			WO 1995-US15025	W 19951116
			US 1997-836628	A1 19970516
			US 1997-978682	A3 19971126

OTHER SOURCE(S): MARPAT 135:137519

GI



AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R¹ = H, (fluoro)alkyl, cyano, CO₂R³, etc.; R² = H, alkyl, OR³, etc.; R³ = H, (fluoro)alkyl, etc.; R⁴ = e.g., (4-arylpiperidinopropyl)carbamoyl; X = O, S, (alkyl)imino] and analogs thereof were prepared Over 60 synthetic examples were provided. Thus 1,6-dihydro-5-(cyanoethoxycarbonyl)-4-ethyl-6-(4-nitrophenyl)-2-methoxypyrimidine (prepared in 3 steps) was treated with 4-nitrophenylchloroformate (acylation at N1) followed by the corresponding substituted piperidine to give the N1 carboxamide intermediate. The cyanoethoxycarbonyl function was saponified and converted to the 5-carboxamido derivative II. Thus, title compound II had pK_i of 9.74 for binding at human α lc receptors in vitro. Treatment of benign prostatic hyperplasia is a claimed use of the invention.


IT 179482-02-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α lc antagonists)

RN 179482-02-1 CAPLUS

CN 1,5(6H)-Pyrimidinedicarboxylic acid, 6-(1,3-benzodioxol-5-yl)-2-methoxy-4-methyl-, 1-(4-nitrophenyl) 5-(phenylmethyl) ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/075,909

DOCUMENT NUMBER: 135:61230
TITLE: 1-(Aminophenyl)-2-pyrrolidones as integrin inhibitors
INVENTOR(S): Dominguez, Celia; Chen, Guoqing; Xi, Ning; Xu, Shimin;
Han, Nianhe; Liu, Qingyian; Huang, Qi; Siegmund,
Aaron; Handley, Michael; Liu, Longbin; Kiselyov,
Alexander S.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044230	A1	20010621	WO 2000-US33515	20001211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002019402	A1	20020214	US 2000-732546	20001208
CA 2393310	AA	20010611	CA 2000-2393310	20001211
AU 2001020835	A5	20010625	AU 2001-20835	20001211
EP 1240158	A1	20020918	EP 2000-984165	20001211
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003535036	T2	20031125	JP 2001-544720	20001211
PRIORITY APPLN. INFO.:			US 1999-170824P	P 19991214
			US 2000-732546	A 20001208
			WO 2000-US33515	W 20001211
OTHER SOURCE(S):	MARPAT 135:61230			
GI				



AB Title compds. are effective in the prophylaxis and treatment of diseases or conditions mediated by integrin receptors, such as $\alpha v \beta 3$, $\alpha v \beta 5$, $\alpha v \beta 6$, $\alpha 5 \beta 1$. Thus, the pyrrolidinone I [R = PhNHCO, R1 = H] was prepared by treating I [R = H, R1 = Et] with PhNCO and ester hydrolysis.

IT 345298-02-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


10/075,909

(Reactant or reagent)

(preparation of 1-(aminophenyl)-2-pyrrolidones as integrin inhibitors)

RN 345298-02-4 CAPLUS

CN 1,3(2H,4H)-Pyrimidinedicarboxylic acid, 2-[[3-[4-[[[1-(1,3-benzodioxol-5-yl)-3-methoxy-3-oxopropyl]amino]carbonyl]-2-oxo-1-pyrrolidiny]phenyl]imino]dihydro-, bis(1,1-dimethylethyl) ester (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:604917 CAPLUS

DOCUMENT NUMBER: 129:231019

TITLE: Preparation of N-heterocyclic derivatives as NOS inhibitors

INVENTOR(S): Arnaiz, Damian O.; Baldwin, John J.; Davey, David D.; Devlin, James J.; Dolle, Roland Ellwood, III; Erickson, Shawn David; McMillan, Kirk; Morrissey, Michael M.; Ohlmeyer, Michael H. J.; Pan, Gonghua; Paradkar, Vidyadhar Madhav; Parkinson, John; Phillips, Gary B.; Ye, Bin; Zhao, Zuchun; et al.

PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA; Pharmacopeia, Inc.; et al.

SOURCE: PCT Int. Appl., 358 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9837079	A1	19980827	WO 1998-US3176	19980219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2281545	AA	19980827	CA 1998-2281545	19980219
AU 9861749	A1	19980909	AU 1998-61749	19980219
AU 732969	B2	20010503		
EP 968206	A1	20000105	EP 1998-906555	19980219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
GB 2338957	A1	20000112	GB 1999-19686	19980219

10/075,909

NZ 337861	A	20010223	NZ 1998-337861	19980219
NO 9903996	A	19991018	NO 1999-3996	19990819
HK 1025952	A1	20020412	HK 2000-104236	20000711
US 2003027794	A1	20030206	US 2002-121758	20020412
US 2003060452	A1	20030327	US 2002-121212	20020412
US 2003069210	A1	20030410	US 2002-122072	20020412
PRIORITY APPLN. INFO.:			US 1997-808975	A2 19970219
			US 1998-25124	A 19980217
			WO 1998-US3176	W 19980219
			US 1999-383813	A3 19990826

OTHER SOURCE(S): MARPAT 129:231019
GI




I

AB N-Heterocyclic derivs. I [U = N, CR5 (R5 = H, halo, alkyl, optionally substituted aralkyl or aryl, etc.); V = NR4, S, O, CHR4 (R4 = H, alkyl, aryl, aralkyl, cycloalkyl); W = N, CH; X, Y, Z = N, CR19 (R19 = H, alkyl, cyclopropyl, halo, haloalkyl); A = R1, OR1, CONR1R2, PO(NR1R2)2, NR1COR2, etc. (R1, R2 = H, optionally substituted alkyl or cycloalkyl, etc. or R1R2N = N-heterocyclyl); B = CR17(CHR15)mQR3 (m = 1-4, R3 = H, alkyl, cycloalkyl, optionally substituted aryl, etc.; R15, R17 = H, alkyl; Q = CO, O, C:NR1, etc.); N-heterocyclyl; C = (CHR12)q(CHR13)r (q, r = 0 or 1; R12, R13 = H, alkyl); or B = C = null; R14, R20 = H, alkyl; n = 1-3] were prepared as inhibitors of nitric oxide synthase. Thus, N-[(1,3-benzodioxol-5-yl)methyl]-1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetamide was prepared by reaction of 1-(3-aminophenyl)imidazole, 7-chloro-3-oxoheptanoic acid Et ester, and piperonylamine.

IT 212639-01-5P 212639-02-6P 212639-04-8P
212639-06-0P 212639-15-1P 212639-33-3P
212639-35-5P 212639-49-1P 212645-12-0P
212646-48-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclic derivs. as NOS inhibitors)

RN 212639-01-5 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-(1-methylethyl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)




RN 212639-02-6 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[6-chloro-2-


10/075,909

(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)




RN 212639-04-8 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)




RN 212639-06-0 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)



RN 212639-15-1 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-[2-(1,3-benzodioxol-5-yl)ethyl]-N1-cyclohexyl-4-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/075,909


RN 212639-33-3 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 212639-35-5 CAPLUS

CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 212639-49-1 CAPLUS


CN 1,2-Piperazinedicarboxamide, N2-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 212645-12-0 CAPLUS


CN 1,3-Piperazinedicarboxamide, N3-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N1-propyl- (9CI) (CA INDEX NAME)

10/075,909



RN 212646-48-5 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-(1,3-benzodioxol-5-ylmethyl)-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:473181 CAPLUS

DOCUMENT NUMBER: 125:142759

TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α 1c antagonists

INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9614846	A1	19960523	WO 1995-US15025	19951116
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,				

10/075,909

MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
TM, TT
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
NE, SN, TD, TG
CA 2205384 AA 19960523 CA 1995-2205384 19951116
AU 9642398 A1 19960606 AU 1996-42398 19951116
AU 714640 B2 20000106
EP 790826 A1 19970827 EP 1995-940748 19951116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
CN 1173132 A 19980211 CN 1995-197348 19951116
JP 10510247 T2 19981006 JP 1996-516354 19951116
JP 3200070 B2 20010820
BR 9509700 A 19981103 BR 1995-9700 19951116
HU 77941 A2 19981228 HU 1998-1222 19951116
CA 2237774 AA 19970522 CA 1996-2237774 19961115
WO 9717969 A1 19970522 WO 1996-US18573 19961115
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG
AU 9710558 A1 19970605 AU 1997-10558 19961115
AU 714287 B2 19991223
ZA 9609612 A 19970721 ZA 1996-9612 19961115
EP 866708 A1 19980930 EP 1996-941406 19961115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2000500470 T2 20000118 JP 1997-519157 19961115
NO 9702236 A 19970701 NO 1997-2236 19970515
FI 9702087 A 19970714 FI 1997-2087 19970515
US 6268369 B1 20010731 US 1997-836628 19970516
US 5942517 A 19990824 US 1997-978682 19971126
US 6228861 B1 20010508 US 1998-68782 19981110
US 6248747 B1 20010619 US 1999-291553 19990414
US 6727257 B1 20040427 US 2000-730458 20001205
PRIORITY APPLN. INFO.: US 1994-340611 A 19941116
WO 1995-US15025 W 19951116
US 1996-648770 A 19960516
WO 1996-US18573 W 19961115
US 1997-836628 A1 19970516
US 1997-978682 A3 19971126
OTHER SOURCE(S): MARPAT 125:142759
GI




AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R1 = H, (fluoro)alkyl, cyano, ,CO2R3, etc.; R2 = H, alkyl, OR3, etc.; R3 = H, (fluoro)alkyl, etc.; R4 = e.g, (4-arylpiperidinopropyl)carbamoyl; X = O, S, (alkyl)imino] were prepared Thus, title compound II had pKi of 9.74 for binding at human α lc receptors in vitro.

IT 179482-02-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α lc antagonists)

RN 179482-02-1 CAPLUS

CN 1,5(6H)-Pyrimidinedicarboxylic acid, 6-(1,3-benzodioxol-5-yl)-2-methoxy-4-methyl-, 1-(4-nitrophenyl) 5-(phenylmethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1977:139991 CAPLUS

DOCUMENT NUMBER: 86:139991

TITLE: Syntheses of isoalloxazines, alloxazines, toxoflavines, and fervenulins by oxidative cyclization of the Michael-type adducts from substituted 6-aminouracils and azo-compounds

AUTHOR(S): Yoneda, Fumio; Sakuma, Yoshiharu; Nagamatsu, Tomohisa; Mizumoto, Shunjiro

CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan






SOURCE: Journal of the Chemical Society, Perkin Transactions

10/075,909

1: Organic and Bio-Organic Chemistry (1972-1999)
(1976), (22), 2398-402
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE:
LANGUAGE:
GI

Journal
English



AB Treatment of Michael adducts from 6-aminouracil derivs. and EtO₂CN:NC₂OEt with Pb(OAc)₄ or PhNO₂ gave the title products. E.g., I (R = Ph, N:CHPh) (R₁ = Me, R₂ = H; R₁ = H, R₂ = Me) gave 44-84% II-V, resp. The reactions occurred by oxidative rearrangement followed by thermal or photochem. cyclization.

IT 62583-97-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of)

RN 62583-97-5 CAPLUS

CN 1,2-Hydrazinedicarboxylic acid, 1-[4-[(1,3-benzodioxol-5-ylmethylene)methylhydrazino]-1,2,3,6-tetrahydro-1-methyl-2,6-dioxo-5-pyrimidinyl]-, diethyl ester (9CI) (CA INDEX NAME)

